Patents Represented by Attorney Cephalon, Inc.
  • Patent number: 8298577
    Abstract: Opiate containing dosage forms and methods using same are described. These dosage forms include substantially less opiates by weight than known oral formulations. These dosage forms are intended for oral administration across the oral mucosa.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: October 30, 2012
    Assignee: Cephalon, Inc.
    Inventor: Derek Moe
  • Patent number: 7205001
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: April 17, 2007
    Assignee: Polarx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Marmelstein
  • Patent number: 7179493
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: February 20, 2007
    Assignee: PolaRx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Marmelstein
  • Patent number: 7163703
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: January 16, 2007
    Assignee: PolaRx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Mermelstein
  • Patent number: 7141555
    Abstract: Mixtures of a modafinil compound with a cyclodextrin, methods for their use, and compositions thereof are disclosed, along with complexes comprising a modafinil compound and a cyclodextrin which are taste-masked and suitable for oral consumption in an aqueous solution.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: November 28, 2006
    Assignee: Cephalon, Inc.
    Inventors: Martin J. Jacobs, Piyush R. Patel
  • Patent number: 7132116
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: November 7, 2006
    Assignee: PolaRx Biopharmaceuticals Inc.
    Inventors: Ralph M. Ellison, Fred H. Mermelstein
  • Patent number: 7122679
    Abstract: The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer.
    Type: Grant
    Filed: May 8, 2001
    Date of Patent: October 17, 2006
    Assignee: Cephalon, Inc.
    Inventors: Mark A. Ator, Ron Bihovsky, Sankar Chatterjee, Derek Dunn, Robert L. Hudkins
  • Patent number: 7087647
    Abstract: Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: August 8, 2006
    Assignee: Cephalon, Inc.
    Inventors: Matthew S. Miller, Thomas E. Scammell
  • Patent number: 7057069
    Abstract: The present invention provides processes for the preparation of modafinil which includes the step of reacting benzhydrylthiol and chloroacetamide.
    Type: Grant
    Filed: March 28, 2005
    Date of Patent: June 6, 2006
    Assignee: Cephalon, Inc.
    Inventors: Denis Largeau, Gilles Oddon